Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)

dc.contributor.authorCantón, Rafael
dc.contributor.authorLoza, Elena
dc.contributor.authorArcay, Ricardo M.
dc.contributor.authorCercenado, Emilia
dc.contributor.authorCastillo, Francisco Javier
dc.contributor.authorCisterna, Ramón
dc.contributor.authorGálvez Benítez, Lidia
dc.contributor.authorGonzález Romo, Fernando
dc.contributor.authorHernández Cabezas, Alicia
dc.contributor.authorRodríguez Lozano, Jesús
dc.contributor.authorSuárez Barrenechea, Ana Isabel
dc.contributor.authorTubau, Fe
dc.contributor.authorDíaz Regañón, Jazmín
dc.contributor.authorLópez Mendoza, Diego
dc.contributor.authorSMART-Spain Working Group
dc.date.accessioned2021-07-19T09:04:42Z
dc.date.available2021-07-19T09:04:42Z
dc.date.issued2021-03-01
dc.date.updated2021-07-16T08:27:00Z
dc.description.abstractObjective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn0214-3429
dc.identifier.pmid33645948
dc.identifier.urihttps://hdl.handle.net/2445/179214
dc.language.isoeng
dc.publisherSociedad Española de Quimioterapia
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.37201/req/019.2021
dc.relation.ispartofRevista Española de Quimioterapia, 2021, vol. 34, num. 3, p. 228-237
dc.relation.urihttps://doi.org/10.37201/req/019.2021
dc.rightscc by-nc (c) Cantón, Rafael et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationPseudomonas
dc.subject.classificationResistència als medicaments
dc.subject.classificationMedicaments antibacterians
dc.subject.classificationEpidemiologia
dc.subject.otherPseudomonas
dc.subject.otherDrug resistance
dc.subject.otherAntibacterial agents
dc.subject.otherEpidemiology
dc.titleAntimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
canton01mar2021.pdf
Mida:
493.5 KB
Format:
Adobe Portable Document Format